(相关资料图)
复星医药(600196):控股子公司复宏汉霖获伊匹木单抗生物类似药HLX13(即重组抗CTLA-4全人单克隆抗体注射液)药品临床试验批准
2023-05-23
2023-05-16
2023-05-09
2023-05-04
2023-02-28
2022-11-08
2022-11-07
2022-11-04
2022-11-03
2022-11-02
2022-11-01
2022-10-31
2022-10-28
2022-10-27
2022-10-26
2022-10-21
2022-10-20
2022-10-19
2022-10-18
2022-10-17
2022-10-14
2022-10-11
2022-10-10
2022-10-09
2022-10-08
2022-09-30
2022-09-28
2022-09-27
2022-09-26
2022-09-21
2022-09-20
2023-06-27